Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer

VernacularTitle:IL-21和Tfh细胞介导NSCLC免疫治疗的研究进展
Author: LIU XINGKAI ^{1
,

2} ; ZHANG YIFAN ; ZHANG XIN ; HE GONGHAO ; CAI WENKE
Author Information

1. 650032 昆明,中国人民解放军联勤保障部队第九二○医院胸心外科
2. 650500 昆明,昆明医科大学
Keywords: Lung neoplasms; Follicular helper T cells; Interleukin-21; Immune checkpoint proteins
From: Chinese Journal of Lung Cancer 2024;27(7):550-558
CountryChina
Language:Chinese
Abstract: Non-small cell lung cancer(NSCLC)is a prevalent and aggressive global malignancy.Conventional sur-gical treatments,radiotherapy,chemotherapy,and targeted therapies often fall short in halting disease progression due to inher-ent limitations,resulting in suboptimal prognosis.Despite the advent of immunotherapy drugs offering new hope for NSCLC treatment,current efficacy remains insufficient to meet all patient needs.Therefore,actively exploring novel immunotherapeu-tic approaches to further reduce mortality rates in NSCLC patients has become a crucial focus of NSCLC research.This article aims to systematically review the anti-tumor effects ofinterleukin-21 and follicular helper T cells in NSCLC immunotherapy by summarizing and analyzing relevant literatures from both domestic and international sources,as well as exploring the potential for enhancing NSCLC treatment prospects through immune checkpoint regulation via immunotherapeutic means.